Navigation Links
Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
Date:6/2/2009

href="http://www.advancedlifesciences.com" target="_new">www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 866.713.8567 (domestic) or 617.597.5326 (international). The passcode for the conference call is 15573457. A replay of the conference call will be available until July 10, 2009. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 27483036. Investors are advised to dial into the call at least ten minutes prior to the call to register.

About Restanza

Restanza is a novel, once-a-day, oral antibiotic that is under review for approval by the FDA for the treatment of CAP. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide-, and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About Community Acquired Pneumonia (CAP)

CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. CAP affects 5.6 million patients in the United States each year, with 10 million physician visits and 2 million hospitalizations occurring annually.

Macr
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
11. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015 This report analyzes ... the following Product Segments: Non-Powered Breast Pumps, and Powered Breast ... Canada , Japan , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
(Date:4/20/2015)... 20, 2015 This report analyzes the worldwide markets ... Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report ... , Japan , Europe ... World. Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:4/20/2015)... April 20, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... results for the Phase 1 study of MM-302, ... breast cancer.  The results were presented today by ... oral session at the 2015 American Association for ... Philadelphia, PA. Data described the safety ...
Breaking Medicine Technology:World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14World ADME-Toxicology Testing Industry 2World ADME-Toxicology Testing Industry 3World ADME-Toxicology Testing Industry 4World ADME-Toxicology Testing Industry 5World ADME-Toxicology Testing Industry 6World ADME-Toxicology Testing Industry 7World ADME-Toxicology Testing Industry 8World ADME-Toxicology Testing Industry 9World ADME-Toxicology Testing Industry 10World ADME-Toxicology Testing Industry 11World ADME-Toxicology Testing Industry 12World ADME-Toxicology Testing Industry 13World ADME-Toxicology Testing Industry 14World ADME-Toxicology Testing Industry 15World ADME-Toxicology Testing Industry 16World ADME-Toxicology Testing Industry 17World ADME-Toxicology Testing Industry 18World ADME-Toxicology Testing Industry 19Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5
... BioTrends Research Group, Inc. announces the release of the ... and Cimzia report. The survey was completed by ... qualitative interviews with a subset (n=20) of the survey respondents to ... employed to differentiate the products. Over the course of the ...
... , ATLANTA, Dec. 23 Alimera Sciences, Inc., a privately ... commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from ... The FAME Study consists of two Phase 3 pivotal clinical ... Iluvien in the treatment of diabetic macular edema (DME). The ...
Cached Medicine Technology:Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 2Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 2Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 4Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 5Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 6
(Date:4/21/2015)... The American Society for Dermatologic Surgery ... S. Brandt, M.D., by setting up two memorial funds ... since 1982, died earlier this month at age 65 ... provide opportunities for ASDS members, industry and any interested ... Dr. Brandt held so dear. , “Dr. Brandt was ...
(Date:4/21/2015)... 2015 United Benefit Advisors (UBA), ... is pleased to welcome Power Kunkle Benefits Consulting ... Kunkle and Jeff Power have been committed to ... confidence of more than 450 clients. For Power ... planning, dedicated stewardship, ethical consulting, and measurable results. ...
(Date:4/21/2015)... One of the most difficult aspects ... food cravings. Many diets end badly due to dieters’ ... Some attempt to eat more often throughout the day, ... regular intervals. While this approach does work for many, ... after a meal. For those who are having trouble ...
(Date:4/21/2015)... April 21, 2015 In early April, ... blue lights to draw attention to a growing global ... this time is the unique educational needs of individuals ... is wide and diverse and each autistic person is ... constant. That is, the educational and emotional needs of ...
(Date:4/21/2015)... San Rafael, CA (PRWEB) April 21, 2015 ... of players at the beautiful Governor’s Academy prep school ... clinic running July 10-12, 2015, for boys entering grades ... staff compliment and supplement the players’ fall coaching. ... extremely skilled athletes. Not only are these the most ...
Breaking Medicine News(10 mins):Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:Diet Doc Introduces New Neuro Balance, A Proprietary Diet Aid to Help Dieters Eliminate Food Cravings 2Health News:Diet Doc Introduces New Neuro Balance, A Proprietary Diet Aid to Help Dieters Eliminate Food Cravings 3Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 2Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 3Health News:In Light of Autism Awareness Month,The Glenholme School Illuminates the Benefits of Therapeutic Boarding School for Students on the Spectrum 4Health News:US Sports Camps and The Northeast Football Clinic Announce 2015 Lineman/Linebacker Clinic Schedule 2
... , FRIDAY, Nov. 5 (HealthDay News) -- People undergoing cancer ... possible and avoid exertion, to save all their strength to ... physicians and researchers now say that people who remain physically ... to beat cancer. The positive evidence for exercise during ...
... , FRIDAY, Nov. 5 (HealthDay News) -- Falls from tree ... an Ohio State University study. Researchers analyzed 130 hunting-related ... found that 50 percent of injuries were caused by falls, ... Among the other findings: , Gunshot wounds accounted ...
... , FRIDAY, Nov. 5 (HealthDay News) -- Over ... inflammatory kidney disorder known as lupus nephritis have vastly improved, ... with lupus nephritis, which is a complication that can occur ... can now expect a better quality of life, without many ...
... sent to physicians the moment they ordered a blood ... that is often false-positive for the elderly, according to a ... of Managed Care . The D-dimer test, combined ... of deep vein thrombosis (blood clots in veins, otherwise known ...
... Nov. 5 (HealthDay News) -- New genetic mapping of ... a particular gene mutation are particularly well-skilled in the ... between a specific variation of the so-called "PCSK6 gene" ... hard evidence to suggest that there could be an ...
... DC A large national study finds that screening current ... deaths from lung cancers by 20 percent. One potential ... up tumors at an early stage. The study was ... the country including Georgetown Lombardi Comprehensive Cancer Center, a part ...
Cached Medicine News:Health News:To Best Fight Cancer, New Guidelines Urge Exercise 2Health News:To Best Fight Cancer, New Guidelines Urge Exercise 3Health News:To Best Fight Cancer, New Guidelines Urge Exercise 4Health News:Lupus Kidney Disorder Treatment Improved Over Decade: Review 2Health News:Real-time physician electronic alerts reduce unnecessary blood testing in elderly patients 2Health News:Real-time physician electronic alerts reduce unnecessary blood testing in elderly patients 3Health News:Research Suggests Link Between 'Handedness' and Dyslexia 2Health News:National study shows CT screening of former, current smokers reduces lung cancer deaths 2Health News:National study shows CT screening of former, current smokers reduces lung cancer deaths 3
... The modular Doro headrest system ... and non-invasive applications in head ... be adapted to all standard ... decisive advantages and improvements in ...
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Children's hospital hand drill, hexagonal handle, twist drill diameter 4.2 mm....
Hudson Drill hand drill....
Medicine Products: